Modular Nanotechnologies for Cancer Drug Screening

用于癌症药物筛选的模块化纳米技术

• 批准号: 6333988
• 负责人: CYNTHIA C. BAMDAD
• 金额: $ 38.8万
• 依托单位: MINERVA BIOTECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6333988
• 关键词: angiogenesis inhibitors; biomedical equipment development; biomimetics; colorimetry; drug screening /evaluation; high throughput technology; nanotechnology; technology /technique development

DESCRIPTION: (provided by applicant) We propose to further develop, multiplex, and apply novel nanotechnologies, demonstrated in Phase I. These technologies will, for the first time, enable effective, high throughput drug screening that will identify novel compounds that block ligand-receptor interactions on the surface of live cells. We will target specific cell surface receptors that have been implicated in tumorigenesis, metastasis and angiogenesis. A second in vitro nano-based technology will be extended to screen for synthetic mimics of protein-based drugs, such as antibodies and natural products. These assays will be specifically developed to identify synthetic mimics of known angiogenesis inhibitors, for which large-scale production costs may be prohibitive. Large, chemically diverse drug libraries will be screened as a part of this project. PROPOSED COMMERCIAL APPLICATION: The technologies demonstrated in Phase I have significant commercial potential. One technology enables high throughput screening for a class of target receptors implicated in cancer that have heretofore been difficult to assay in a relevant way. The other technology offers a direct approach to identifying synthetic mimics of drugs that are too costly to produce in mass quantities. The technologies are modular and thus easily adapted to facilitate screening of a wide variety of targets without further modification to the platform technology. Both the technologies as well as any drug leads identified would be of extreme interest to pharmaceutical companies.

描述：（申请人提供） 我们建议进一步开发、复合和应用新的纳米技术， 在第一阶段展示。这些技术将首次使 有效、高通量的药物筛选，以鉴定新化合物 阻断活细胞表面的配体-受体相互作用。我们将 靶向特异性细胞表面受体， 肿瘤发生、转移和血管生成。第二种体外纳米基 技术将扩展到筛选蛋白质基的合成模拟物， 药物，如抗体和天然产物。这些试验将 专门开发用于鉴定已知血管生成的合成模拟物 抑制剂，其大规模生产成本可能过高。大号、 作为该项目的一部分，将筛选化学成分多样化的药物库。 拟定商业应用： 第一阶段展示的技术具有巨大的商业潜力。 一 技术能够高通量筛选涉及的一类靶受体 在迄今为止难以以相关方式测定的癌症中。 另 技术提供了一种直接的方法来识别药物的合成模拟物， 大量生产成本高。 这些技术是模块化的，因此很容易适应 为了便于筛选各种各样的靶标，而无需进一步修饰 平台技术 这两种技术以及任何确定的药物线索将是 对制药公司非常感兴趣